[e-farmacos] Rosiglitazona en el NEJM: RECORD interino y editoriales

["Canas, Martin" <macanas@netverk.com.ar>]

Estiamdas y estimados,

Flor de revuelo y material de lectura para la semana

Home y cols decieron hacer un analisis interino no planificado cuyos hallazgos fueron no concluyentes  y con datos insuficientes:

"Our interim findings from this ongoing study were inconclusive regarding 
the effect of rosiglitazone on the overall risk of hospitalization or death 
from cardiovascular causes. There was no evidence of any increase in death 
from either cardiovascular causes or all causes. Rosiglitazone was associated with an increased risk of heart failure. The data were insufficient to determine whether the drug was associated with an increase 
in the risk of myocardial infarction"

El articulo:

P.D. Home and Others  Rosiglitazone Evaluated for Cardiovascular Outcomes - 
An Interim Analysis

en:
http://content.nejm.org/cgi/content/full/NEJMoa073394

y los editoriales
J.M. Drazen, S. Morrissey, and G.D. Curfman  Rosiglitazone - Continued 
Uncertainty about Safety

http://content.nejm.org/cgi/reprint/NEJMe078118v1.pdf


D.M. Nathan  Rosiglitazone and Cardiotoxicity - Weighing the Evidence
http://content.nejm.org/cgi/reprint/NEJMe078117v1.pdf

B.M. Psaty and C.D. Furberg  The Record on Rosiglitazone and the Risk of 
Myocardial Infarction
http://content.nejm.org/cgi/reprint/NEJMe078116v1.pdf

Saludos,

Martin

Martin Canas
GAPURMED
La Plata 
(Argentina)
macanas@netverk.com.ar